Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.54 |
| ▸ | HTR3B | O95264 | 2/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.54 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 4/20 | 0.45 |
| ▸ | NOS1 | P29475 | 4/20 | 0.45 |
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507738 | 0.78 | ALOX15 (0.48) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3644220 | 0.76 | CYP2C19 (0.43) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3962045 | 0.76 | SLC22A2 (0.54) | SLC22A2SLC22A1SLC22A3PLAUNOS3 | |
| SCHEMBL163160 | 0.76 | HTR3E (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10794558 | 0.76 | HTR3E (0.64) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL54470 | 0.75 | HTR3E (0.50) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3676774 | 0.74 | HTR3E (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Bicarbonate SCHEMBL27729117 | 0.73 | HTR3E (0.83) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2332722 | 0.73 | GSK3B (0.48) | CYP2C19HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL230956 | 0.71 | PLG (0.54) | CYP2C19CYP2D6TDP1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005077372-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | WO | disclosed |
| EP-1254899-B1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-0346683-A1 | Pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0127162-B1 | COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4842985-A | COUPLER HAVING DYE MOIETY WITH SHIFTED MAXIMUM ABSORPTION WAVELENGTH, HUE-FIXING COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| US-4585728-A | 2-EQUIVALENT MAGENTA COUPLER AND AMINE | FUJI PHOTO FILM CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4555479-A | CONTAINING 5-PYRAZOLONE TYPE MAGENTA COUPLERS AND NITROGEN COMPOUND-PREVENTION STAINING | FUJI PHOTO FILM CO., LTD. (JP) | 1985-11-26 | — | — | US | disclosed |
| EP-0127162-A2 | Color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CYP2C19 1048/4885HTR3E 1363/4885HTR3B 1754/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | CYP2C19 2592/4885HTR3E 1435/4885HTR3B 1456/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CYP2C19 1048/4885HTR3E 1363/4885HTR3B 1754/4885 |
| US-20050192282-A1 | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | CCL2, CCL11, CCL5 | CYP2C19 4290/4885HTR3E 3174/4885HTR3B 3063/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CYP2C19 804/4885HTR3E 3671/4885HTR3B 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.